59 related articles for article (PubMed ID: 21737656)
1. Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer.
Luo W; Schork NJ; Marschke KB; Ng SC; Hermann TW; Zhang J; Sanders JM; Tooker P; Malo N; Zapala MA; Dziewanowska ZE; Negro-Vilar A; Meglasson MD
Anticancer Res; 2011 Jun; 31(6):2303-11. PubMed ID: 21737656
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.
Govindan R; Crowley J; Schwartzberg L; Kennedy P; Williams C; Ekstrand B; Sandler A; Jaunakais D; Bolejack V; Ghalie R
J Clin Oncol; 2006 Oct; 24(30):4848-54. PubMed ID: 17050870
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
6. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
Dragnev KH; Petty WJ; Shah SJ; Lewis LD; Black CC; Memoli V; Nugent WC; Hermann T; Negro-Vilar A; Rigas JR; Dmitrovsky E
Clin Cancer Res; 2007 Mar; 13(6):1794-800. PubMed ID: 17363535
[TBL] [Abstract][Full Text] [Related]
7. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
8. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
[TBL] [Abstract][Full Text] [Related]
9. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
12. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW
Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
Bi N; Yang M; Zhang L; Chen X; Ji W; Ou G; Lin D; Wang L
Clin Cancer Res; 2010 Apr; 16(8):2383-90. PubMed ID: 20332326
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide single nucleotide polymorphism analysis of lung cancer risk detects the KLF6 gene.
Spinola M; Leoni VP; Galvan A; Korsching E; Conti B; Pastorino U; Ravagnani F; Columbano A; Skaug V; Haugen A; Dragani TA
Cancer Lett; 2007 Jun; 251(2):311-6. PubMed ID: 17223258
[TBL] [Abstract][Full Text] [Related]
15. A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer.
Landvik NE; Hart K; Skaug V; Stangeland LB; Haugen A; Zienolddiny S
Carcinogenesis; 2009 Jul; 30(7):1186-92. PubMed ID: 19461122
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study.
Tseng RC; Hsieh FJ; Shih CM; Hsu HS; Chen CY; Wang YC
Cancer; 2009 Jul; 115(13):2939-48. PubMed ID: 19408343
[TBL] [Abstract][Full Text] [Related]
17. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
18. XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer.
Zhu LB; Xu Q; Hong CY; Yue Z; Zhang Y; Ye HN; Yuan Y
Anticancer Drugs; 2010 Aug; 21(7):669-73. PubMed ID: 20571354
[TBL] [Abstract][Full Text] [Related]
19. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.
Zienolddiny S; Campa D; Lind H; Ryberg D; Skaug V; Stangeland LB; Canzian F; Haugen A
Carcinogenesis; 2008 Jun; 29(6):1164-9. PubMed ID: 18258609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]